Evaluation of the Intubating Laryngeal Airway in Children
Launched by UNIVERSITY OF BRITISH COLUMBIA · Nov 1, 2010
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
Hypothesis: The Air-Q® intubating laryngeal airway (Air-Q® ILA) will act as an excellent conduit for fibreoptic intubation.
Background: The laryngeal mask airway (LMA) is used during pediatric anesthesia for routine and difficult airway management. The ideal pediatric LMA device would provide excellent sealing at low pressure; facilitate easy endotracheal intubation; and be available in pediatric sizes. Such a device would be an invaluable addition to difficult pediatric airway management plans and, by increasing the likelihood of quickly and effectively securing the difficult airway, and ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA I-III
- • Ideal body weight as determined from weight/height centile curves (\>3rd \& \<97th centiles). Wei
- • Elective surgery
- • Appropriate subject and procedure for airway management by endotracheal intubation.
- Exclusion Criteria:
- • ASA status IV-V
- • Emergency surgery
- • Anticipated difficult intubation
- • Contraindication to LMA placement
- • Aspiration risk; gastro-esophageal reflux disease
- • Clinically significant pulmonary disease
- • Coagulopathy
- • Distorted airway anatomy judged likely to compromise LMA placement
- • Allergy to any LMA components
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Simon White, Dr.
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials